-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Benzinga·08/14/2026 17:19:56
Listen to the news
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.